Besides, Cheng et al. discovered that for EGFR-TKI-resistant NSCLC patients, immunochemotherapy was more effective in young patients without T790M, liver metastasis, and brain metastasis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.